Scientific program

Click HERE to view the Congress Book

Session Key:

Pre-Congress Workshop Plenary Session Parallel Session Free Papers Session Industry Symposium

Thursday, October 13, 2022

08:30-11:30 Pre-Congress Workshop 1:
Breast cancer in young women: Understanding differences to optimise outcomes
Hall A
(Great Hall 1)
Chairpersons Sanjeev Kumar, Sydney, Australia
Jenny Gilchrist, Sydney, Australia
08:30-09:00 Fertility and breast cancer
Ying Li, Sydney, Australia
09:00-09:30 Management of menopausal side effects
Martha Hickey, Melbourne, Australia
09:30-10:00 Goserelin (Zoladex) in young women
Prudence Francis, Melbourne, Australia
10:00-10:20 Coffee Break 
10:20-11:10 The art of oncology: Treating young women with a focus on pregnancy after breast cancer
Ann Partridge, Boston, MA, USA
11:10-11:30 Q&A

 

 08:30-11:30 Pre-Congress Workshop 2:
Contrast based breast imaging
Hall C
(Room M1)
Chairperson Nick Repin, Lismore, Australia
08:30-08:35 Welcome
Nick Repin, Lismore, Australia
08:35-08:55 Implementation of Contrast Imaging: Challenges and opportunities
Allison Rose,
Melbourne, Australia
08:55-09:40 Indications for Contrast Imaging
Julia Camps Herrero,
Valencia, Spain
09:40-10:00 Contrast Enhanced Mammography (CEM) in surveillance
Allison Rose,
Melbourne, Australia
10:00-10:30 Coffee Break 
10:30-11:30 MDM hypothetical-case presentations and discussions
Julia Camps Herrero, Valencia, Spain
Allison Rose,
Melbourne, Australia
Bruce Mann, Melbourne, Australia
Michael Christie, Melbourne, Australia

 

 08:30-11:30 Pre-Congress Workshop 3:
Bioethical dilemmas: Q&A, cases and discussion
Hall D
(Room M2)
Chairperson Jennifer O’Sullivan, Sydney, Australia
08:30-10:00 Cases and discussion
David Kirchhoffer, Brisbane, Australia
Bridget Pratt, Brisbane, Australia
10:00-10:20 Coffee Break 
10:20-11:30 Cases and discussion contd.

 

11:30-12:30 Lunch Break 

 

 12:30-15:30 Pre-Congress Workshop 4:
Hereditary breast cancer
Hall A
(Great Hall 1)
Chairperson Nirmala Pathmanathan, Sydney, Australia 
12:30-13:20 Management of common genetic predisposition syndromes
Milita Zaheed, Sydney, Australia
13:20-14:00 The “extended panel” of genetic testing; implications and management
Helen Mar Fan, Brisbane, Australia
14:00-14:20 Coffee Break 
14:20-14:55 Molecular mechanisms, diagnostic and therapeutic implications of hereditary breast cancer syndromes
Sunil Lakhani, Brisbane, Australia
14:55-15:30 Psychological impact and management of patients with hereditary breast cancer
Jemma Gilchrist, Sydney, Australia

 

12:30-15:30 Pre-Congress Workshop 5:
Radiation oncology: Clinical updates and clinical challenges
Hall C
(Room M1)
Chairperson Marcus Dreosti, Adelaide, Australia 
Speakers:
Frank A. Vicini, Royal Oak, MI, USA
Boon Chua, Sydney, Australia
  Topics:
1. DCIS – Clinical decision making for adjuvant radiation therapy reflections on BIG 3-07/TROG 07.01 and the evolving use of biomarker tools and consideration of potentially radiation refractory disease
2. Tailoring the management of low-risk invasive disease – where do we sit in 2022?  Perspectives on partial breast radiation and techniques and radiation omission data and controversies
3. Optimising locoregional radiation therapy following neoadjuvant systemic therapy in node positive patients including updates from NSABP-51 and other trials
14:00-14:20 Coffee Break 
14:20-15:30 Q&A

 

12:30-15:30 Pre-Congress Workshop 6:
Challenging communication
Hall D
(Room M2)
Chairperson Jenny Gilchrist, Sydney, Australia
12:30-14:00 Cases and discussion
Jane Turner,
Brisbane, Australia
14:00-14:20 Coffee Break 
14:20-15:30 Cases and discussion contd.

 

15:30-16:00 Break 

 

16:00-16:15 Congress Opening Hall A
(Great Hall 1)
Chairperson: Bruce Mann, Melbourne, Australia
Welcome to Country
Welcome from Congress chairpersons

 

16:15-17:45 Plenary Session 1:
Neoadjuvant therapy
Hall A
(Great Hall 1)
Chairpersons Elisabeth Elder, Sydney, Australia
Richard de Boer,
Melbourne, Australia
 16:15-16:45
16:15
16:25
16:35
Debate: That cT1cN0 HER2+ve and TNBC should have NAST
Yes: Alistair Ring, London, UK
No: Nicholas Wilcken, Sydney, Australia
Discussion
16:45-17:15 Lessons learnt: The UK experience of Neo Adjuvant Endocrine Therapy (NAET) during the COVID-19 pandemic
Stephen Johnston, London, UK
 17:15-17:45
17:15
17:25
17:35
Debate: That LN positive patients achieving pCR with NAST should still receive regional nodal radiotherapy
Yes: Frank A. Vicini, Royal Oak, MI, USA
No: Steven David, Melbourne, Australia
Discussion

 

 17:45 Networking Reception

Friday, October 14, 2022

07:30-08:30 Morning Industry Symposium:
The role of Enhertu (trastuzumab-deruxtecan) in changing the treatment paradigm for HER2-positive Metastatic Breast Cancer
Supported by AstraZeneca
Please note breakfast will be served  prior to the session.
Hall A
(Great Hall 1)

 

07:30-08:30 Morning Industry Symposium:
DCISionRT: Personalising treatment for women with DCIS
Supported by GenesisCare and PreludeDX
Please note breakfast will be served  prior to the session.
Hall B
(Great Hall 2)

 

07:30-08:30 Morning Industry Symposium:
Risk adjusted screening
Supported by Hologic
Please note breakfast will be served  prior to the session.
Hall C
(Room M1)
 08:30-09:30 Parallel Session 2:
Screening
Hall A
(Great Hall 1)
 Chairpersons Allison Rose, Melbourne, Australia
Owen Ung,
Brisbane, Australia
08:30-08:45 Tailored screening: The Netherlands experience
Ritse Mann, Nijmegen, The Netherlands
 08:45-09:15
08:45
08:55
09:05
Debate: That women at low risk for breast cancer should only be screened every 5 years
Yes: Christobel Saunders, Melbourne, Australia
No: Jane Fox, Melbourne, Australia
Discussion
 09:15-09:30 Risk adjusted screening: Considerations and lessons from COVID-19
Carolyn Nickson, Melbourne, Australia

 

 08:30-09:30 Parallel Session 3:
Fear of cancer recurrence
Hall B
(Great Hall 2)
Chairpersons Kerry Shanahan, Melbourne, Australia
Belinda Yeo, Melbourne, Australia
08:30-08:50 Fear of cancer recurrence: What is it, and how common is it?
Jane Turner, Brisbane, Australia
08:50-09:10 Is it possible to conquer fear of recurrence?
Charlotte Tottman, Adelaide, Australia
09:10-09:30 Discussion

 

08:30-09:30 Industry Symposium:
Evolution of treatment sequencing in patients with mTNBC
Supported by Gilead
Hall C
(Room M1)

 

 09:30-11:00 Plenary Session 4:
Genetics
Hall A
(Great Hall 1)
 Chairpersons Nicole McCarthy, Brisbane, Australia
Jane Fox, Melbourne, Australia
 09:30-10:10
09:30
09:45
10:00
Debate: That ~all patients with breast cancer should be panel tested for germline mutations
Yes: Yoland Antill, Melbourne, Australia
No: Helen Mar Fan, Brisbane, Australia
Discussion
10:10-10:35 The ‘new genes’: What do they mean for patients and families?
Paul James, Melbourne, Australia
10:35-11:00 Tailored treatments for BRCA+ early breast cancer: The time is now!
Mark Robson, New York, NY, USA

 

11:00-11:30 Coffee break, poster viewing and exhibition visit

 

 11:30-12:30 Parallel Session 5:
Lymphoedema
Hall A
(Great Hall 1)
 Chairpersons Kerry Patford, Benalla, Australia
Rajiv Dave, Manchester, UK
 11:30-11:50 What is the evidence behind advice regarding lymphoedema prevention?
Louise Koelmeyer, Sydney, Australia
11:50-12:10 Evidence based treatment modalities for established lymphoedema: What works? What doesn’t?
Robyn Box, Brisbane, Australia
 12:10-12:30 Discussion

 

11:30-12:30 Industry Symposium:
Improving outcomes in high-risk HER2-positive patients post-KATHERINE
Supported by an educational/research sponsorship by Roche
Hall B
(Great Hall 2)

 

 11:30-12:30 Industry Symposium:
Touch and go: Removing the guesswork in detecting residual cancer
Supported by OncoRes
Hall C
(Room M1)

 

12:30-13:30 Lunch break, poster viewing and exhibition visit

 

 13:30-14:30 Parallel Session 6:
DCIS
Hall A
(Great Hall 1)
 Chairpersons Steven David, Melbourne, Australia
Caroline Baker,
Melbourne, Australia
 13:30-14:00
13:30
13:40
13:50
Debate: That most patients with DCIS should have radiotherapy after Breast Conserving Surgery
Yes: Boon Chua, Sydney, Australia
No: Alastair Thompson, Houston, TX, USA
Discussion
14:00-14:30
14:00
14:10
14:20
Debate: That active surveillance for low risk DCIS is a reasonable option
Yes: Jocelyn Lippey, Melbourne, Australia
No: Heidi Peverill, Brisbane, Australia
Discussion

 

13:30-14:30 Parallel Session 7:
Triple negative breast cancer

Hall B
(Great Hall 2)
 Chairpersons Nicholas Wilcken, Sydney, Australia
Catherine Shannon, Brisbane, Australia
13:30-14:10
13:30
13:45
14:00
Debate: Immunotherapy should be part of standard of care in neoadjuvant treatment for TN ESBC
Yes: Javier Cortes, Madrid, Spain
No: Alistair Ring, London, UK
Discussion
14:10-14:30 TNBC subtypes and their clinical significance
Nirmala Pathmanathan, Sydney, Australia

 

 13:30-14:30 Parallel Session 8:
Free Papers: Supportive care
Hall C
(Room M1)
 Chairpersons Yoland Antill, Melbourne, Australia
Marissa Stevens, Melbourne, Australia
13:30-13:40 “Linking risk with screening” – the impact of an online decision aid for risk-stratified breast screening on understanding, acceptance and decision-making
Jocelyn Lippey, Melbourne, Australia
13:40-13:50 What is women with breast cancers’ experience and perception of genitourinary symptoms?
Antonia Pearson, Sydney, Australia
13:50-14:00 Estimating end of life care costs to different funders for breast cancer patients in Queensland, Australia: A data linkage study
Shafkat Jahan, Brisbane, Australia
14:00-14:10
Supporting LGBTQI communities impacted by breast cancer: Results and translational  outcomes of the out with cancer study
Julie Rae, Red Hill, Australia
14:10-14:20 Patient perceptions of physical rehabilitation and its method of delivery for a variety of adverse physical effects following breast cancer surgery
Deirdre McGhee, Wollongong, Australia
14:20-14:30
No association between breast pain and breast cancer. A prospective cohort study of 10,830 patients presenting to a Breast Cancer Diagnostic Clinic
Rajiv Dave, Manchester, UK

 

 14:30-15:50 Parallel Session 9:
Adjuvant endocrine therapy
Hall A
(Great Hall 1)
Chairpersons Prudence Francis, Melbourne, Australia
Alistair Ring,
London, UK
14:30-15:05
14:30
14:40
14:50
Debate: That CDK4/6i’s should be part of adjuvant treatment of high risk ER+HER2- early breast cancer
Yes: Richard de Boer, Melbourne, Australia
No: Nick Zdenkowski, Newcastle, Australia
Discussion
15:05-15:15 Real world evidence and its value in breast cancer management
Sheau Wen Lok, Melbourne, Australia
15:15-15:50
15:15
15:25
15:35
Debate: That all pre-menopausal women with LN+ve ER+HER2- EBC should have adjuvant chemotherapy
Yes: Nicole McCarthy, Brisbane, Australia
No: Belinda Yeo, Melbourne, Australia
Discussion

 

 14:30-15:50 Parallel Session 10:
Free Papers: Locoregional therapy
Hall C
(Room M1)
 Chairpersons Michael Alvarado, San Francisco, CA, USA
Jill Dietz, Pittsburgh, PA, USA
14:30-14:40 Outcome of atypical or b3 lesions in Breastscreen NSW
Richard Chou, Condell Park, Australia
14:40-14:50 Contrast Enhanced Mammography in further assessment of screen-detected breast cancer
Caroline MacCallum, Melbourne, Australia
14:50-15:00 Comparison of local recurrence after simple and skin-sparing mastectomy performed in patients with pure ductal carcinoma in situ
Rajiv Dave, Manchester, UK
15:00-15:10 Using Radio-Occult Lesion Localization (ROLL) techniques to identify the clipped node in Targeted Axillary Dissections (TAD)
Alec Winder, Townsville, Australia
15:10-15:20 Comparing direct-to-implant and two-stage breast reconstruction in the Australian breast device registry
Sheymonti Hoque, Melbourne, Australia
15:20-15:30 Trends and variations in post-mastectomy breast reconstruction rates in Australia over 10 years
Nirmal Dayaratna, Sydney, Australia
15:30-15:40 Surgical outcomes of post-mastectomy radiotherapy following immediate prosthetic breast reconstruction: Six-year experience
Negin Sedaghat, Sydney, Australia
15:40-15:50 Therapeutic mammaplasty with contralateral symmetrising reduction mammaplasty: Oncologically safe with satisfied patients
Susannah Graham, Camperdown, Australia

 

15:50-16:10 Coffee break, poster viewing and exhibition visit

 

 16:10-17:30 Parallel Session 11:
Imaging
Hall A
(Great Hall 1)
Chairpersons Jane Fox, Melbourne, Australia
Alastair Thompson, Houston, TX, USA
16:10-16:30 How can imaging assist management of patients receiving neoadjuvant therapy?
Julia Camps Herrero, Valencia, Spain
16:30-16:50 The PROSPECT of selective omission of RT based on MRI findings
Bruce Mann, Melbourne, Australia
16:50-17:10 That Contrast Enhanced Mammography (CEM) is ready for prime time
Allison Rose, Melbourne, Australia
17:10-17:30 Discussion

 

16:10-17:30 Parallel Session 12:
Metastatic breast cancer
Hall B
(Great Hall 2)
Chairpersons Nick Zdenkowski, Newcastle, Australia
Javier Cortes, Madrid, Spain
16:10-16:30 Should molecular testing of tumours be routine for patients with metastatic breast cancer?
Yes: Elgene Lim, Sydney, Australia
16:30-17:15
16:30
16:45
17:00
Debate: Routine imaging vs clinical follow-up for high risk EBC: Time to change the paradigm?
Yes: Sally Baron-Hay, Sydney, Australia
No: Catherine Shannon, Brisbane, Australia
Discussion
17:15-17:30 What’s the optimal timing for Bone Targeted Agents in MBC?
Belinda Yeo, Melbourne, Australia

 

Saturday, October 15, 2022

07:30- 08:30 Morning Industry Symposium:
Future-proofing breast surgical guidance with Sentimag®
A total magnetic conversion
Supported by Endomag/GRC Surgical
Please note breakfast will be served  prior to the session.
Hall A
(Great Hall 1)

 

07:30-08:30 Morning Industry Symposium:
Time to start CDK4&6 inhibition in EBC: Verzenio in HR+ HER2- node positive EBC at high risk of recurrence
Supported by Lilly
Please note breakfast will be served  prior to the session.
Hall B
(Great Hall 2)

 

07:30-08:30 Morning Industry Symposium:
The role of the nurse in assessing, triaging and managing metastatic TNBC
Supported by Gilead
Please note breakfast will be served  prior to the session.
Hall C
(Room M1)

 

 08:30-10:00 Parallel Session 13:
Controversies in reconstruction
Hall A
(Great Hall 1)
Chairpersons Kirsten Pilatti, Melbourne, Australia
Sanjay Warrier, Sydney, Australia
 08:30-09:10
08:30
08:40
08:50
Debate: That immediate breast reconstruction prior to post-mastectomy radiotherapy should be avoided
Yes: Caroline Baker, Melbourne, Australia
No: Dean Trotter, Melbourne, Australia
Discussion
 09:10-09:30 Patient-reported outcomes to guide decisions regarding breast reconstruction
Douglas MacMillan, Nottingham, UK
09:30-09:50 Consumer voice informing the future of breast reconstruction Australia
Sam Mills, Melbourne, Australia
Jodi Steel, Sydney, Australia
09:50-10:00 Discussion

 

 08:30-10:00 Parallel Session 14:
Survivorship
Hall B
(Great Hall 2)
 Chairpersons Jenny Gilchrist, Sydney, Australia
Jocelyn Lippey, Melbourne, Australia
08:30-08:35 Introduction
Jenny Gilchrist, Sydney, Australia
08:35-08:45 What matters most to consumers?
Andrea Smith,
Sydney, Australia
08:45-08:55 GP perspective
Elysia Thornton-Benko, Sydney, Australia
08:55-09:05 Survivorship MoC based around nurse led clinics
Kerry Shanahan, Melbourne, Australia
09:05-09:15 McGrath model of survivorship care
Kerry Patford, Benalla, Australia 
09:15-09:25 #JustTextMe: Empowering women’s health during survivorship
Anna Singleton, Sydney, Australia
09:25-09:35 IBIS
Raymond Chan, Adelaide, Australia
09:35-10:00 Discussion

 

 08:30-10:00 Parallel Session 15:
Free Papers: Medical oncology
Hall C
(Room M1)
Chairpersons Nick Zdenkowski, Newcastle, Australia
Sally Baron-Hay, Sydney, Australia
08:30-08:40 Update on the use of topical estrogens in symptomatic women with early breast cancer
Antonia Pearson, Sydney, Australia
08:40-08:50 Contrast Enhanced Mammography in breast cancer surveillance
Kenneth Elder, Melbourne, Australia
08:50-09:00 Contralateral breast cancer: Influence of molecular subtype, clinical features and treatment given in a single institution study
Mohammad Amira, Perth, Australia
09:00-09:10 The effect of age and menstrual cycling on gene expression profiling tests
Wendy Ingman, Adelaide, Australia
09:10-09:20 Concordance between core needle biopsy and surgical excision for breast cancer tumor grade and biomarkers
Aswin Shanmugalingam, Sydney, Australia
09:20-09:30 The design and development of an individualised training program for Metastatic Breast Cancer (MBC) nursing incorporating remote and onsite learning experiences during a pandemic
Gillian Kruss, Sydney, Australia
09:30-09:40 ATNEC – patient experience sub-study (IRSCTN: 36585784):
What patients think about taking part in breast cancer treatment de-escalation trials?
Janet Dunn, Coventry, UK
09:40-09:50 Monitoring of breast cancer treatment response by analysis of breast cancer-derived extracellular vesicles
Katherine Wongtrakul-Kish, Sydney, Australia
09:50-10:00 Enhanced toxicity with trastuzumab emtansine and concurrent adjuvant radiotherapy: Non-consecutive case series
Steven David,
Melbourne, Australia

 

 10:00-11:00 Parallel Session 16:
Locoregional therapy
Hall A
(Great Hall 1)
Chairpersons Heidi Peverill, Brisbane, Australia
Caroline Baker, Melbourne, Australia
10:00-10:30

10:00
10:10
10:20

Debate: That patients with heavy axillary nodal disease pre-NACT should have axillary dissection irrespective of response to NACT
Yes: Alastair Thompson, Houston, TX, USA
No: Bruce Mann, Melbourne, Australia
Discussion
 10:30-11:00
10:30
10:40
10:50
Debate: That omission of SNB should be considered for all women >70 with clinically negative axillae
Yes: Melanie Walker, Melbourne, Australia
No: Sanjay Warrier, Sydney, Australia
Discussion

 

10:00-11:00 Industry Symposium:
A CDK4/6i is a ‘once in a lifetime treatment’ for patients with HR +ve HER2 -ve breast cancer
Supported by Novartis
Hall B
(Great Hall 2)

 

11:00-11:30 Coffee break, poster viewing and exhibition visit

 

 11:30-13:00 Parallel Session 17:
Local therapy
Hall A
(Great Hall 1)
Chairpersons Christobel Saunders, Melbourne, Australia
Melanie Walker, Melbourne, Australia
11:30-12:30 Time to cut the wire?
 11:30 That hook needles are perfectly satisfactory for lesion localisation
Owen Ung, Brisbane, Australia
11:40 The case for SCOUT
Cindy Mak, Sydney, Australia
11:50 The case for Magseed
Michael Alvarado, San Francisco, CA, USA
12:00 The case for ROLLIS
Rhea Liang, Gold Coast, Australia
12:10 Discussion
12:30-13:00
12:30
12:40
12:50
Debate: That five-fraction radiotherapy should be standard of care for most patients
Yes: Alice Ho, Boston, MA, USA
No: Frank A. Vicini, Royal Oak, MI, USA
Discussion

 

11:30-13:00 Parallel Session 18:
HER2 positive disease
Hall B
(Great Hall 2)
Chairpersons Nicole McCarthy, Brisbane, Australia
Elgene Lim, Sydney, Australia
11:30-12:15
11:30
11:45
12:00
Debate: Do anthracyclines still have a place in the treatment of early stage HER2+ve BC?
Yes: Nick Murray, Adelaide, Australia
No: Fran Boyle, Sydney, Australia
Discussion
 12:15-12:35 HER2 heterogeneity: Interpretation of low HER2 amplification and HER+ve hotspots
Cameron Snell, Melbourne, Australia
 12:35-13:00 Management of brain mets in those with HER2+ve disease
Rebecca Dent, Singapore, Singapore

 

13:00-14:00 Lunch break, poster viewing and exhibition visit

 

13:10-13:55 Lunch Industry Symposium:
Innovative approaches to help improve patient outcomes: Case-based discussion
Supported by 3M
Lunch boxes will be served to session participants.
Hall B
(Great Hall 2)

 

10:30-17:00 Breast Cancer Network Australia 
Hall C (Room M1)

 

 14:00-15:00 Plenary Session 19:
Palliative care
Hall A
(Great Hall 1)
Chairpersons Antonia Pearson, Sydney, Australia
Nick Murray, Adelaide, Australia
14:00-14:30
14:00
14:10
14:20
Debate: That palliative care should ditch the word ‘palliative’
Yes: Brian Le, Melbourne, Australia
No: Andrew Broadbent, Gold Coast, Australia
Discussion
14:30-15:00 Medicinal cannabis in advanced cancer: Pot or panacea?
Phillip Good, Brisbane, Australia

 

 15:00-16:15 Plenary Session 20:
Breast cancer 2030
Hall A
(Great Hall 1)
 Chairpersons Bruce Mann, Melbourne, Australia
Richard de Boer,
Melbourne, Australia
15:00-15:15 Early detection in 2030
Ritse Mann, Nijmegen, The Netherlands
15:15-15:30 A pathologist’s view of breast cancer in 2030
Sunil R. Lakhani, Brisbane, Australia
15:30-15:45 Systemic therapy in 2030
Prudence Francis, Melbourne, Australia
15:45-16:00 Locoregional therapy in 2030
Douglas MacMillan, Nottingham, UK
16:00-16:15 A consumer’s perspective of breast cancer in 2030
Kirsten Pilatti, Melbourne, Australia

 

16:15-16:30 Congress closing and Award presentation
Hall A
(Great Hall 1)
 Chairpersons Bruce Mann, Melbourne, Australia
Melanie Walker, Melbourne, Australia
Elisabeth Elder, Sydney, Australia

 

Skip to content